Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 15 studies | 21% ± 7% | |
fibroblast | 15 studies | 31% ± 9% | |
endothelial cell | 15 studies | 27% ± 10% | |
macrophage | 14 studies | 25% ± 11% | |
natural killer cell | 12 studies | 21% ± 4% | |
astrocyte | 12 studies | 41% ± 19% | |
classical monocyte | 10 studies | 25% ± 10% | |
oligodendrocyte | 9 studies | 60% ± 21% | |
microglial cell | 9 studies | 38% ± 12% | |
naive B cell | 8 studies | 21% ± 4% | |
oligodendrocyte precursor cell | 8 studies | 39% ± 19% | |
smooth muscle cell | 8 studies | 29% ± 11% | |
GABAergic neuron | 7 studies | 49% ± 25% | |
glutamatergic neuron | 7 studies | 54% ± 26% | |
non-classical monocyte | 6 studies | 31% ± 11% | |
monocyte | 6 studies | 22% ± 7% | |
pericyte | 6 studies | 25% ± 6% | |
myeloid cell | 6 studies | 42% ± 7% | |
epithelial cell | 6 studies | 33% ± 12% | |
retina horizontal cell | 6 studies | 28% ± 8% | |
Mueller cell | 6 studies | 37% ± 13% | |
conventional dendritic cell | 5 studies | 33% ± 16% | |
mast cell | 5 studies | 28% ± 9% | |
amacrine cell | 5 studies | 34% ± 7% | |
retinal rod cell | 5 studies | 19% ± 3% | |
T cell | 4 studies | 17% ± 2% | |
neutrophil | 4 studies | 26% ± 7% | |
CD4-positive, alpha-beta T cell | 4 studies | 22% ± 5% | |
mature NK T cell | 4 studies | 18% ± 4% | |
retinal ganglion cell | 4 studies | 33% ± 10% | |
retinal bipolar neuron | 4 studies | 20% ± 2% | |
retinal cone cell | 4 studies | 27% ± 9% | |
dendritic cell | 4 studies | 35% ± 15% | |
interneuron | 4 studies | 65% ± 22% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 22% ± 4% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 25% ± 5% | |
CD8-positive, alpha-beta T cell | 3 studies | 23% ± 3% | |
memory B cell | 3 studies | 18% ± 1% | |
precursor B cell | 3 studies | 23% ± 3% | |
connective tissue cell | 3 studies | 21% ± 4% | |
innate lymphoid cell | 3 studies | 18% ± 2% | |
retinal pigment epithelial cell | 3 studies | 26% ± 6% | |
adipocyte | 3 studies | 36% ± 12% | |
GABAergic amacrine cell | 3 studies | 34% ± 9% | |
glycinergic amacrine cell | 3 studies | 32% ± 3% | |
type I pneumocyte | 3 studies | 22% ± 5% | |
pancreatic A cell | 3 studies | 24% ± 3% | |
neuron | 3 studies | 20% ± 3% | |
gamma-delta T cell | 3 studies | 22% ± 5% | |
immature B cell | 3 studies | 28% ± 17% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2171.26 | 245 / 245 | 100% | 14.89 | 501 / 502 |
lung | 100% | 2893.90 | 578 / 578 | 100% | 11.99 | 1151 / 1155 |
ovary | 100% | 3558.72 | 180 / 180 | 100% | 9.52 | 428 / 430 |
breast | 100% | 2896.17 | 459 / 459 | 99% | 22.56 | 1111 / 1118 |
brain | 99% | 1634.76 | 2623 / 2642 | 100% | 15.90 | 705 / 705 |
esophagus | 100% | 2026.41 | 1445 / 1445 | 99% | 15.13 | 181 / 183 |
thymus | 100% | 2091.64 | 653 / 653 | 98% | 12.75 | 595 / 605 |
adrenal gland | 100% | 2305.30 | 258 / 258 | 98% | 13.99 | 226 / 230 |
kidney | 100% | 1088.33 | 89 / 89 | 98% | 15.94 | 884 / 901 |
stomach | 100% | 1658.31 | 359 / 359 | 98% | 13.28 | 280 / 286 |
pancreas | 100% | 1216.05 | 327 / 328 | 98% | 12.05 | 174 / 178 |
uterus | 100% | 2982.12 | 170 / 170 | 97% | 10.57 | 447 / 459 |
intestine | 100% | 2137.49 | 966 / 966 | 97% | 11.50 | 512 / 527 |
bladder | 100% | 2420.62 | 21 / 21 | 97% | 9.99 | 489 / 504 |
liver | 100% | 1410.74 | 226 / 226 | 97% | 9.45 | 392 / 406 |
skin | 100% | 2782.48 | 1809 / 1809 | 93% | 14.35 | 440 / 472 |
adipose | 100% | 2980.26 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2310.15 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 2474.33 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2290.00 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 10.08 | 45 / 45 |
peripheral blood | 99% | 3347.57 | 920 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 7.03 | 28 / 29 |
heart | 97% | 1437.89 | 831 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 75% | 9.72 | 60 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0043154 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_2000973 | Biological process | regulation of pro-B cell differentiation |
GO_0001783 | Biological process | B cell apoptotic process |
GO_0031929 | Biological process | TOR signaling |
GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
GO_0032007 | Biological process | negative regulation of TOR signaling |
GO_0001932 | Biological process | regulation of protein phosphorylation |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0009267 | Biological process | cellular response to starvation |
GO_0031334 | Biological process | positive regulation of protein-containing complex assembly |
GO_1905672 | Biological process | negative regulation of lysosome organization |
GO_1904263 | Biological process | positive regulation of TORC1 signaling |
GO_0002327 | Biological process | immature B cell differentiation |
GO_0002904 | Biological process | positive regulation of B cell apoptotic process |
GO_0032008 | Biological process | positive regulation of TOR signaling |
GO_0030183 | Biological process | B cell differentiation |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0019899 | Molecular function | enzyme binding |
GO_0008047 | Molecular function | enzyme activator activity |
GO_0051087 | Molecular function | protein-folding chaperone binding |
GO_0042030 | Molecular function | ATPase inhibitor activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FNIP1 |
Protein name | Folliculin-interacting protein 1 Folliculin interacting protein 1 |
Synonyms | KIAA1961 |
Description | FUNCTION: Binding partner of the GTPase-activating protein FLCN: involved in the cellular response to amino acid availability by regulating the non-canonical mTORC1 signaling cascade controlling the MiT/TFE factors TFEB and TFE3 . Required to promote FLCN recruitment to lysosomes and interaction with Rag GTPases, leading to activation of the non-canonical mTORC1 signaling . In low-amino acid conditions, component of the lysosomal folliculin complex (LFC) on the membrane of lysosomes, which inhibits the GTPase-activating activity of FLCN, thereby inactivating mTORC1 and promoting nuclear translocation of TFEB and TFE3 (By similarity). Upon amino acid restimulation, disassembly of the LFC complex liberates the GTPase-activating activity of FLCN, leading to activation of mTORC1 and subsequent inactivation of TFEB and TFE3 . Together with FLCN, regulates autophagy: following phosphorylation by ULK1, interacts with GABARAP and promotes autophagy . In addition to its role in mTORC1 signaling, also acts as a co-chaperone of HSP90AA1/Hsp90: following gradual phosphorylation by CK2, inhibits the ATPase activity of HSP90AA1/Hsp90, leading to activate both kinase and non-kinase client proteins of HSP90AA1/Hsp90 . Acts as a scaffold to load client protein FLCN onto HSP90AA1/Hsp90 . Competes with the activating co-chaperone AHSA1 for binding to HSP90AA1, thereby providing a reciprocal regulatory mechanism for chaperoning of client proteins . Also acts as a core component of the reductive stress response by inhibiting activation of mitochondria in normal conditions: in response to reductive stress, the conserved Cys degron is reduced, leading to recognition and polyubiquitylation by the CRL2(FEM1B) complex, followed by proteasomal (By similarity). Required for B-cell development . . |
Accessions | J3KNG8 ENST00000307954.12 ENST00000511848.1 [Q8TF40-2] ENST00000307968.11 [Q8TF40-3] Q8TF40 ENST00000510461.6 [Q8TF40-1] |